Serialization authenticates the package. MedSnap authenticates the pills inside.
Serialization authenticates the package. MedSnap authenticates the pills inside.
DSCSA and the EU Falsified Medicines Directive mandate package-level serialization and verification. The systems these frameworks require do not authenticate the actual medication inside. In high-volume automated environments — central fill robotics, pouch packaging, returns-to-stock — this gap becomes operational risk at scale.
When the gap between package verification and content authentication goes unaddressed, the failure modes are operational:
A supply chain substitution arrives under a valid NDC. An upstream stocking error places look-alike tablets in the wrong channel. Bulk oral solids are loaded into the wrong robot canister. Returned medications re-enter stock without content verification.
Barcodes confirm the label. Weight checks confirm the count. Nothing authenticates that the tablets or capsules are what they claim to be.
MedSnap uses patented machine vision to analyze the "production fingerprint" of solid oral dosage forms. The system extracts 24 visual features across five categories — size, shape, color, imprint, and texture — and applies statistical hypothesis testing to compare a field sample against reference models built from verified authentic product.
A calibration surface enables reproducible measurements across devices and lighting environments. The system operates offline, on standard mobile hardware, with results in seconds. Each authentication produces a documented evidentiary record.
This is not image matching.
This is forensic-grade production source authentication.
Protected by U.S. Patents 9,111,357 and 9,466,004.
Validated Against the Hardest Test Cases Available
MedSnap was developed by Indicator Sciences and validated in laboratory and field settings by top-10 global pharmaceutical product-security teams in the US and EU. Challenge materials included globally sourced, visually indistinguishable falsified and look-alike medicines curated over many years. Across these evaluations: zero false accepts, zero false rejects. References available under NDA.
An independent evaluation conducted in partnership with the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) and the Medicine Quality Research Group in Lao PDR reported 100% sensitivity and 100% specificity across 48 samples in field conditions — including falsified antimalarials and field-sourced antibiotics from local pharmacies. Read the evaluation here.
Multi-dimensional clustering of 698 falsified samples collected over five years from global sources revealed shared production fingerprints among samples from common illicit manufacturing sources — demonstrating that falsified supply chains leave detectable signatures, and that MedSnap's analytical resolution can find them.
In certain evaluations, MedSnap differentiated authentic product by manufacturing site — distinguishing between factories in different countries producing the same medication. This is production source differentiation: the foundation for contract manufacturer oversight and supply chain forensics.
Watch the system — running locally on standard mid-range 2020 mobile hardware — rapidly distinguish between authentic medication and a visually near-identical falsified substitute.
Click Here for Video Demonstration
The demonstration above was recorded on the legacy iOS platform. The current system operates on Android.
The same authentication engine serves every deployment context. What changes is the workflow.
Automated Pharmacy — Upstream Content Authentication
MedSnap authenticates medications at three upstream checkpoints — receiving, repackaging, and robot loading — before they enter the dispensing system.
By authenticating upstream, the only downstream task remaining is verifying count and detecting damaged pills — a far simpler problem. The false-positive burden that currently consumes pharmacist time when existing vision systems attempt to verify pills through packaging is eliminated.
No Snap, No Release. • No Snap, No Enable. • No Snap, No Restock.
Returns-to-Stock
When medications are returned from patient care areas, automated dispensing overrides, or discharged patients, they must be authenticated before re-entering the pharmacy’s active inventory. MedSnap scans returned medications and blocks restock until authentication is confirmed — closing a known error pathway that no barcode can address.
Supply Chain Integrity and Contract Manufacturer Oversight
Production source differentiation enables verification of manufacturing origin across a distributed supply chain — confirming not just what a medication is, but where it was made. For organizations managing multiple contract manufacturers across multiple geographies, MedSnap provides objective, evidence-based oversight of production sourcing.
Regulatory, Field, and Global Health
Portable, offline-capable authentication producing forensic-grade evidentiary records for regulatory, customs, and law enforcement oversight.
The LOMWRU evaluation in Lao PDR validated a rapid, end-to-end workflow—from initial model creation using local authentic supplies to field deployment and result collection—within a single 72 hour operational window. This deployment successfully proved the system’s ability to protect high-acuity patient populations in LMIC field conditions where falsified medications directly threaten survival.
The platform includes a validated codebase and over 300 pages of engineering documentation covering system architecture, statistical pipeline, device integration, authentication engine, and deployment roadmap.
The documentation is organized for direct delivery to an engineering team. A technology partner can move directly to implementation within a modern framework.
World-class professionals with decades of experience at the intersection of artificial intelligence, healthcare data analytics, and machine vision. The founding team previously built MedMined, a pioneer in AI-guided hospital-acquired infection surveillance and prevention, acquired by Cardinal Health in 2006 for approximately $100MM and now part of BD (Becton, Dickinson and Company).